Future directions in regional treatment strategies for melanoma and sarcoma

References

• Aloia TA, Grubbs E, Onaitis M, Mosca PJ, Cheng TY, Siegler H, Tyler DS. Predictors of outcome after hyperthermic limb perfusion: Role of tumor response. Arch Surg 2005; 140: 1115–1120
   PubMedGoogle Scholar
• Sanki A, Kam P, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma. Ann Surg 2007; 245: 591–596
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, Brunstein F, Gravelan WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939–948
   PubMed Web of Science ®Google Scholar
• Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: Response and survival. World J Surg 1995; 19: 363–368
   PubMed Web of Science ®Google Scholar
• Noorda EM, Vourenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BR. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139: 1237–1242
   PubMedGoogle Scholar
• Takkenberg RB, Vrouenraets BC, van Geel AN, Nieweg OE, Noorda EM, Eggermont AM, Kroon BR. Palliative isolated limb perfusion for isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 2005; 91: 107–111
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JHW, van Geel AN, Eggermont AMM. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-α. EJSO 2006; 32: 371–380
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996; 83: 1319–1328
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavalier F, Moscarelli F, Cavalier R. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551–2561
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BBR, van Geel AN, Eggermont AM, Franklin HR, Hart AA. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115: 39
   PubMed Web of Science ®Google Scholar
• Clark J, Grabs AJ, Parsons PG, Smithers BM, Addison RS, Roberts MS. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994; 4: 365–370
   PubMed Web of Science ®Google Scholar
• Minor DR, Allen RE, Alberts D, Yei-Mei Peng, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55: 2638
   PubMed Web of Science ®Google Scholar
• Benckhuijsen C, Kroon BBR, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157
   PubMed Web of Science ®Google Scholar
• Skene AL, Bulman AS, Williams TR, Thomas JM, Westbury G. Hyperthermic isolated limb perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J. Surg 1990; 7: 765
   Google Scholar
• Fletcher WS, Pommier R, Small K. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res 2004; Suppl.1: 17–19
   Google Scholar
• Hoekstra HJ, Schraffordt Koops H, de Vries LG, van Weerden TW, Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993; 72: 1224–1229
   PubMed Web of Science ®Google Scholar
• Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227
   PubMed Web of Science ®Google Scholar
• Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: Fourteen years’ clinical experience. Ann Surg 1972; 175: 900
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam P. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. EJSO 2004; 30: 1107–1112
   PubMed Web of Science ®Google Scholar
• Briele HA, Djuric M, Jung DT, Mortell T, Patel MK, Das Gupta TK. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985; 45: 1885–1889
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903–907
   PubMed Web of Science ®Google Scholar
• Koops HSKH, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ. Prophylactic isolated limb perfusion for localized, high-risk melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906–2912
   PubMed Web of Science ®Google Scholar
• Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. Cancer: Principles and practice of oncology4th ed, VT DeVita, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1993; 1612
   Google Scholar
• Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. J Surg Oncol 1990; 44: 146–150
   PubMed Web of Science ®Google Scholar
• Leon P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH, Jr. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126: 1461–1468
   PubMedGoogle Scholar
• Day CL, Jr, Harrist TJ, Gorstein F, Sober AJ, Lew RA, Friedman RJ, Pasternack BB, Kopf AW, Fitzpatrick TB, Mihm MC, Jr. Malignant melanoma: Prognostic significance of ‘microscopic satellites’ in the reticular dermis and subcutaneous fat. Ann Surg 1981; 194: 108–112
   PubMed Web of Science ®Google Scholar
• Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm M, Detmar M. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Modern Pathology 2005; 18: 1232–1242
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D, Santinami M, Levene A. Regional non-nodal metastasis of cutaneous melanoma. Eur J Surg Onc 1986; 12: 175–180
   PubMedGoogle Scholar
• Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124: 1051–1055
   PubMedGoogle Scholar
• Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL, Alexander HR. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001; 8: 771–778
   PubMed Web of Science ®Google Scholar
• Hafstrom L, Rudenstam CM, Blomquist E, Ingvar C, Johsson PE, Lagerlot B, Lingholm C, Ringborg V, Westman G, Ostrup L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091–2094
   PubMed Web of Science ®Google Scholar
• Ueno T, Ko SH, Grubbs E, Yoshimoto Y, Augustine C, Abdel-Wahab Z, Cheng T, Abdel-Wahab O, Pruitt SK, Friedman HS, Tyler DS. Modulation of chemotherapy resistance in regional therapy: A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther 2006; 5: 732–738
   PubMed Web of Science ®Google Scholar
• Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab O, Abdel-Wahah Z, Chu E, Pruitt SK, Friedman HS, Dewhirst MK, Tyler DS. Optimizing a novel regional chemotherapeutic agent against melanoma: Hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006; 12: 289–297
   PubMed Web of Science ®Google Scholar
• Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS. Defining regional infusion treatment strategies for extremity melanoma: Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther 2007; 6: 1492–500
   PubMed Web of Science ®Google Scholar
• Lienard D, Lejeune, Delmotte J, Renard N, Ewalenco P. High doses of TNFα in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Onc 1982a; 10: 52
   Google Scholar
• Lienard D, Lejeune F, Ewalenko I. In transit metastases of malignant melanoma treated by high doses of TNFα in combination with Interferon-gamma and melphalan in isolation perfusion. World J Surg 1992b; 16: 234
   PubMed Web of Science ®Google Scholar
• Lienard D, Eggermont AM, Schraffordt KH, Kroon BR, Towse O, Hiemstra S, Schmitz P, Clarke J, Steinmann D, Rosenkaimer F, Lejeune FJ. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-α), Interferon gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 2004; 4Suppl.1: 21–26
   Google Scholar
• Fraker DL, Alexader HR, Ross M, Bartlett DL, Tyler DS, Libutti LS, Boodie A, Briele H, Karakousis G. A phase III trial of isolated limb infusion perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF-α) plus Interferon-gamma (IFN). Ann Surg Onc 2002; 9: S8
   Web of Science ®Google Scholar
• Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, Alexander HR, et al. Prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196–4201
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Schraffordt, Koops H, Klausner M, Kroon BB, Schlay PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 756–764: 764–765, discussion
   Google Scholar
• Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoet S, van Geel AN, Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106: 1776–1784
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, et al. Limb salvage by neoadjuvant isolated limb perfusion with TNFalpha and melphalan for nonresectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26: 669–678
   PubMed Web of Science ®Google Scholar
• Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: Preclinical studies. J Natl Cancer Inst 2004; 96: 1603–1610
   PubMed Web of Science ®Google Scholar
• Hoving S, Brunstein F, Ann de Wiel-Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005; 65: 4300–4308
   PubMed Web of Science ®Google Scholar
• Brunstein F, Hoving S, Aan de Wiel-Ambagtsheer G, de Bruijn EA, Guetens G, Eggermont AM, ten Hagen TL, et al. Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion. Cancer Immunol Immunother 2007; 56: 573–580
   PubMed Web of Science ®Google Scholar
• Taber SW, Polk HC, Jr. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 1997; 4: 440–445
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BBR. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224–231
   PubMedGoogle Scholar
• Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238–47
   PubMed Web of Science ®Google Scholar
• Lindner P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Onc 2002; 9: 127–136
   PubMed Web of Science ®Google Scholar
• Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Onc 2006; 13: 1123–1129
   PubMed Web of Science ®Google Scholar
• Zager JS, Gershenwald JE, Aldrink J, Lin E, Cormier JN, Cheng T, Yoo J, Lee JE, Tyler DS, Ross MI. Isolated limb infusion for locally recurrent and in-transit extremity melanoma: A combined institutional initial experience. Ann Surg Oncol 2006; S13: 84
   Google Scholar
• Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Tsung G, Sanders C, Pruitt S, Seigler H, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: A well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Onc 2007, submitted
   Google Scholar
• Grubbs EG, Ueno T, Abdel-Wahab O, Cheng TY, Pruitt SK, Colvin OM, Friedman HS, Tyler DS. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004; 136(2)210–218
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS. In-transit melanoma: The role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004; 199: 419–427
   PubMed Web of Science ®Google Scholar
• Green J, Vistica D, Young R, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984; 44: 5427–5431
   PubMed Web of Science ®Google Scholar
• Suzukake K, Vistica B, Vistica D. Resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983; 32: 165–167
   PubMed Web of Science ®Google Scholar
• Grubbs E, Ueno T, Abdel-Wahab O, Cheng TY, Pruitt SK, Colvin OM, Friedman HS, Tyler DS. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004; 136: 210–218
   PubMed Web of Science ®Google Scholar
• Tyler DS, Yashimoto Y, Grubbs E, Yoo J, Zipfel P, Selim A, Augustine C. Novel strategies to overcome chemoresistance in regional melanoma therapy by systemic modulation of tumor proteins. Mel Res 2006; 16(Suppl.1)S100
   Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Gore M, Marais R, Gibbens I, James MG, Schwartz B, Bergaminin L. Phase 1 trial of Bay 43-9006 (Sorafenib) combined with DTIC in metastatic melanoma patients. Proc ASCO 2005; 23: 712S, Abstract 7508
   Google Scholar
• Flaherty KT, Brose M, Schuchter L, Tuveson D, Lee R, Schwartz B, Lathia C, Weber B, O’Dwyer P. Phase I/II trial of Bay 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc ASCO 2004; 22: 7507
   Google Scholar
• Lorigan P, Corrie P, Chao D, Nathan P, Ahmad T, Marais R, Burk K, Erlandsson F, Gore M, Eisen T. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Proc ASCO 2006; 24, No. 18S
   Google Scholar
• Agarwala SS, Keilholz U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Patel K, Hauschild A. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Proc ASCO 2007; 25: 8510
   Google Scholar
• Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001–7010
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000–2008
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small cell cancer. J Clin Oncol 2004; 22: 2184–2191
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792–799
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722–4729
   PubMed Web of Science ®Google Scholar
• González CM, Viteri S, Garrán C, Nieto Y, Aristu J, Pomz M, Algarra SM. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab. 2007; 9: 119–120
   Google Scholar
• Terheyden P, Hofmann MA, Weininger M, Brocker EB, Becker JC. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. Journal Cancer Res 2007; 133: 897–901
   PubMed Web of Science ®Google Scholar
• Varker KA, Biber JE, Kefauver C, Jensen R. A randomized phase II trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14: 2367–2376
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian B. Somatic activation of KIT distinct subtypes of melanoma. J Clin Onc 2006; 24: 4340–4346
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins B, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma. Cancer 2006; 106: 2005–2011
   PubMed Web of Science ®Google Scholar
• Berkenblit A, Eder JP, Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 584–590
   PubMed Web of Science ®Google Scholar
• Bild AH, Guang Y, Chang JT, Potti A, Chasse D, Joshi MB, Harpole D, Jr, Lancaster JM, Berchuck A, Olson JA, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353–357
   PubMed Web of Science ®Google Scholar
• Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. NEJM 2006; 355: 570–580
   PubMed Web of Science ®Google Scholar